United States - English - NLM (National Library of Medicine)

sti pharma llc - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 5 mg - escitalopram tablets, usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see clinical studies (14.1)]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram tablets, usp are indicated for the acute treatment of generalized anxiety disorder (gad) in adults [see clinical studies (14.2)]. generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent

United States - English - NLM (National Library of Medicine)

sti pharma llc - isoproterenol hydrochloride (unii: dia2a74855) (isoproterenol - unii:l628tt009w) - isoproterenol hydrochloride injection is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation). (see contraindications ) - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (see contraindications ) - for bronchospasm occurring during anesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (see warnings ) use of isoproterenol hydrochloride injection is contraindicated in patients with tachyarrhythmias; tachycardia or heart block caused by digitalis intoxication; ventricular arrhythmias which require inotropic therapy; and angina pectoris.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - capsules - mycophenolate mofetil 250 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

United States - English - NLM (National Library of Medicine)

sti pharma llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 0.5 mg in 5 ml - allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: atopic dermatitis, bronchial asthma, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, and serum sickness. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, and acute rheumatic carditis. dermatologic diseases bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome), severe psoriasis, and severe seborrheic dermatitis. edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; i

United States - English - NLM (National Library of Medicine)

sti pharma llc - triprolidine hydrochloride (unii: yan7r5l890) (triprolidine - unii:2l8t9s52qm), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - triprolidine hydrochloride 1.25 mg in 5 ml - triacin-c is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. triacin-c is contraindicated under the following conditions: codeine sulfate is contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy. this drug should not be used in newborn or premature infants. antihistamines should not be used to treat lower respiratory tract symptoms, including asthma. hypersensitivity to (1) codeine phosphate or other narcotics; (2) triprolidine hydrochloride or other antihistamines of similar chemical structure; or (3) sympathomimetic amines, including pseudoephedrine. sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary artery disease and in patients on monoamine oxidase (mao) inhibitor therapy (see precautions - drug interactions ). like other medications containing a narcotic, triacin-c is controlled by the drug enforcemen

United States - English - NLM (National Library of Medicine)

sti pharma llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. for the treatment of acute otit

United States - English - NLM (National Library of Medicine)

sti pharma llc - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - doxycycline hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis. to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other tetracyclines.

United States - English - NLM (National Library of Medicine)

sti pharma llc - hydroxyzine hydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia. hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral hydroxyzine h